Targeting multiple receptors in glioblastoma treatment
Multi-receptor Targeting of Glioblastoma
This study is testing a new way to treat glioblastoma, a tough type of brain cancer, by using a special method to deliver targeted treatments directly to the tumor, aiming to make the therapy work better while reducing side effects for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wake Forest University Health Sciences NIH-funded |
| Lab location | 1 site (Winston-Salem, United States) |
| Project ID | NIH-10914805 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment for glioblastoma, a type of brain cancer that is difficult to treat. The approach involves delivering targeted cytotoxins directly to the tumor using a method called convection-enhanced delivery (CED). Researchers have identified specific receptors that are over-expressed in glioblastoma cells, and they aim to create a compound that can effectively target these receptors to improve treatment outcomes. By using a modified bacterial toxin linked to a receptor-targeting agent, the goal is to enhance the effectiveness of the therapy while minimizing side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who have tumors expressing the targeted receptors.
Not a fit: Patients with glioblastoma who do not express the targeted receptors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in targeting specific receptors in glioblastoma, suggesting that this approach could be a meaningful advancement in treatment.
Where this research is happening
Winston-Salem, United States
- Wake Forest University Health Sciences — Winston-Salem, United States (Active)
Researchers
- Principal investigator: Debinski, Waldemar — Wake Forest University Health Sciences
- Study coordinator: Debinski, Waldemar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.